IPO registrations (S-1, F-1) · Registrants
LianBio
- SEC CIK
- 1831283 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-10-01, last 2021-10-29; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2021-11-02; declared effective 2021-10-29
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- E9
- Business address
- 103 CARNEGIE CENTER DRIVE, SUITE 309, Princeton, NJ 08540
- Ticker
- LIANY (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- LianBio on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per ADS (S-1/A filed 2021-10-29)
- Final price
- $16.00 per ADS, within the range (424B4 filed 2021-11-02, an initial public offering)
- Shares sold
- 20,312,500
- Gross proceeds
- $325,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LIAN
- Lead underwriters
- Goldman Sachs (7,718,750 shares); Jefferies (7,312,500 shares); BofA Securities (4,265,625 shares)
- Syndicate
- Raymond James (1,015,625)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
Filings 9
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-10-01 | S-1 | S-1 (registration) | LianBio | 0001193125-21-289805 ↗ |
| 2021-10-08 | S-1/A | S-1/A (amendment) | LianBio | 0001193125-21-295616 ↗ |
| 2021-10-20 | S-1/A | S-1/A (amendment) | LianBio | 0001193125-21-302493 ↗ |
| 2021-10-27 | S-1/A | S-1/A (amendment) | LianBio | 0001193125-21-308383 ↗ |
| 2021-10-29 | S-1/A | S-1/A (amendment) | LianBio | 0001193125-21-311645 ↗ |
| 2021-10-29 | EFFECT | EFFECT (declared effective) | LianBio | 9999999995-21-004100 ↗ |
| 2021-10-29 | EFFECT | EFFECT (declared effective) | LianBio | 9999999995-21-004102 ↗ |
| 2021-11-02 | 424B4 | 424B4 (final prospectus) | LianBio | 0001193125-21-316916 ↗ |
| 2023-04-27 | EFFECT | EFFECT (declared effective) | LianBio | 9999999995-23-001067 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-10-29 | S-1/A | registration statement | $15.00–$17.00 | 20,312,500 | - | Nasdaq LIAN | 4 | primary document; range, shares headline, cover names 4 | document ↗ | |
| 2021-11-02 | 424B4 | final prospectus | $16.00 | 20,312,500 | $325,000,000 | Nasdaq LIAN | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| C2 Life Sciences LLC | Director,TenPercentOwner; TenPercentOwner | 6 | 2021–2022 | ||
| EDELMAN JOSEPH | Director,TenPercentOwner; TenPercentOwner | 9 | 2021–2024 | ||
| GIANAKAKOS ANASTASIOS | Director | 5 | 2021–2024 | ||
| Jahn Brianne | Officer | Chief Business Officer | 4 | 2021–2023 | |
| Kumar Neil | Director | 2 | 2021 | ||
| Larson Yi | Officer | Chief Financial Officer | 5 | 2021–2023 | |
| LEV LB Holdings GP, LLC | Director,TenPercentOwner; TenPercentOwner | 6 | 2021–2022 | ||
| LEV LB Holdings, LP | Director,TenPercentOwner; TenPercentOwner | 6 | 2021–2022 | ||
| PERCEPTIVE ADVISORS LLC | Director,TenPercentOwner | 9 | 2021–2024 | ||
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director,TenPercentOwner; TenPercentOwner | 8 | 2021–2024 | ||
| Perceptive Venture Advisors, LLC | Director,TenPercentOwner; TenPercentOwner | 6 | 2021–2022 | ||
| Perceptive Xontogeny Venture Fund, LP | Director,TenPercentOwner; TenPercentOwner | 6 | 2021–2022 | ||
| Poukalov Konstantin | Director | 4 | 2021–2024 | ||
| QIAN JIANG | Officer | China General Manager; SVP, China General Manager | 6 | 2021–2023 | |
| Silbermann Susan Michele | Director | 5 | 2021–2024 | ||
| Stone Adam Leo | Director; Director,Officer | Interim CEO | 4 | 2021–2024 | |
| Wang Yizhe | Director,Officer | Chief Executive Officer | 3 | 2021–2023 | |
| Wu Jesse | Director | 2 | 2021 | ||
| Yu Debra | Officer | See Remarks | 3 | 2021–2022 | |
| Chen Wei Wei | Director | 3 | 2022–2023 | ||
| Gu Ehong | Officer | Interim CFO | 2 | 2023–2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-04-05 | LianBio | Pharmaceuticals | Indefinite | $2,999,977 | 1 | 1 |
| 2020-11-12 | LianBio | Pharmaceuticals | $309,999,948 | $269,999,972 | 23 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | LianBio | Form D private offerings | CIK (EXACT) | |
| SEC filer | LianBio | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.